Literature DB >> 21256596

Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.

Weirong Wang1, Josef Vlasak, Yunsong Li, Pavlo Pristatsky, Yulin Fang, Tamara Pittman, Jeanette Roman, Yang Wang, Thomayant Prueksaritanont, Roxana Ionescu.   

Abstract

IgG monoclonal antibodies (mAbs) consist of two Fab fragments and one Fc fragment. The Fab fragments contain the variable regions and are responsible for drug specificity (via antigen binding); the Fc fragment contains constant regions and is responsible for effector functions (via interactions with Fcγ receptors) and extended serum half-life (via interaction with the neonatal Fc receptor, FcRn). There are two conserved methionine (Met) residues located in the FcRn binding site of the Fc fragment. It has been shown previously that oxidation of these two Met residues decreases the binding affinity to FcRn. We have further evaluated the impact of Met oxidation on serum half-lives of two humanized IgG1 mAbs in transgenic mice with human FcRn. Variable oxidation levels were obtained by several procedures: exposure to an oxidizing agent, accumulation during extended refrigerated storage, or chromatographic separation. Our results show that Met oxidation can result in a significant reduction of the serum circulation half-life and the magnitude of the change correlates well with the extent of Met oxidation and changes in FcRn binding affinities. The relatively low levels of Met oxidation accumulated during 3 years of refrigerated storage had minimal impact on FcRn binding and no detectable impact on the serum half-life.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21256596     DOI: 10.1016/j.molimm.2010.12.009

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  64 in total

Review 1.  ADME of biologics-what have we learned from small molecules?

Authors:  Thomayant Prueksaritanont; Cuyue Tang
Journal:  AAPS J       Date:  2012-04-07       Impact factor: 4.009

2.  Recent advances in the construction of antibody-drug conjugates.

Authors:  Vijay Chudasama; Antoine Maruani; Stephen Caddick
Journal:  Nat Chem       Date:  2016-01-04       Impact factor: 24.427

3.  Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

Authors:  Tilman Schlothauer; Petra Rueger; Jan Olaf Stracke; Hubert Hertenberger; Felix Fingas; Lothar Kling; Thomas Emrich; Georg Drabner; Stefan Seeber; Johannes Auer; Stefan Koch; Apollon Papadimitriou
Journal:  MAbs       Date:  2013-05-29       Impact factor: 5.857

Review 4.  Oxidation of therapeutic proteins and peptides: structural and biological consequences.

Authors:  Riccardo Torosantucci; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

Review 5.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

Review 6.  Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration.

Authors:  Ninad Varkhede; Rupesh Bommana; Christian Schöneich; M Laird Forrest
Journal:  J Pharm Sci       Date:  2019-08-10       Impact factor: 3.534

Review 7.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

Review 8.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

9.  Characterization of Aggregation Propensity of a Human Fc-Fusion Protein Therapeutic by Hydrogen/Deuterium Exchange Mass Spectrometry.

Authors:  Richard Y-C Huang; Roxana E Iacob; Stanley R Krystek; Mi Jin; Hui Wei; Li Tao; Tapan K Das; Adrienne A Tymiak; John R Engen; Guodong Chen
Journal:  J Am Soc Mass Spectrom       Date:  2016-08-15       Impact factor: 3.109

10.  Mitigation of Oxidation in Therapeutic Antibody Formulations: a Biochemical Efficacy and Safety Evaluation of N-Acetyl-Tryptophan and L-Methionine.

Authors:  Michelle Z Dion; Danielle Leiske; Vikas K Sharma; Christina L Zuch de Zafra; Cleo M Salisbury
Journal:  Pharm Res       Date:  2018-10-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.